Role of raltegravir in the management of HIV-1 infection
N Lance Okeke1, Charles Hicks21Duke University Medical Center, Department of Hospital Medicine, Durham Regional Hospital, Durham, North Carolina, USA; 2Duke University School of Medicine, Durham, NC, USAAbstract: The development of multiple agents with potent antiretroviral activity against HIV has...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5d6e929b0b704a0394db3b00948044ff |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | N Lance Okeke1, Charles Hicks21Duke University Medical Center, Department of Hospital Medicine, Durham Regional Hospital, Durham, North Carolina, USA; 2Duke University School of Medicine, Durham, NC, USAAbstract: The development of multiple agents with potent antiretroviral activity against HIV has ushered in a new age of optimism in the management of patients infected with the virus. However, the viruses’ dynamic ability to develop resistance against these agents necessitates the investigation of novel targets for viral suppression. Raltegravir represents a first-in-class agent targeting the HIV integrase enzyme, which is responsible for integration of virally encoded DNA into the host genome. Over the last 5 years, clinical trials data has demonstrated an increasing role for raltegravir in the management of both treatment-experienced and treatment-naïve HIV-1-infected patients. This review focuses on the evidence supporting raltegravir’s efficacy in an array of clinical settings. Other HIV-1 integrase inhibitors in development are also briefly discussed.Keywords: HIV, antiretroviral therapy, raltegravir  |
|---|